Sugi Predict

Sugi Predict / Compounds / SCHEMBL2279068

SCHEMBL2279068

SCHEMBL2279068

CC(C)(C)OC(=O)N1CCCC(C)(C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ SCD5 Q86SK9 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PREP P48147 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ NR1H2 P55055 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20482260 1.00 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL6943029 1.00 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL22625915 0.90 HPGD (0.49) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL12373947 0.90 USP2 (0.45) HPGDUSP2SMN1; SMN2USP30SCD5
SCHEMBL17469418 0.90 USP2 (0.45) HPGDUSP2SMN1; SMN2USP30SCD5
SCHEMBL2285992 0.90 USP2 (0.45) HPGDUSP2SMN1; SMN2USP30SCD5
SCHEMBL7483024 0.89 USP2 (0.38) HPGDUSP2SMN1; SMN2MEN1KMT2A
Potassium Ion SCHEMBL7483027 0.89 USP2 (0.38) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL17407192 0.88 HPGD (0.43) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31231172 0.88 HPGD (0.47) HPGDUSP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596551-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY Trasveda Ltd. (KY) 2025-08-06 — — EP disclosed
US-20250114305-A1 LIPIDIC COMPOUNDS, AND USES THEREOF SANOFI (FR) 2025-04-10 — — US disclosed
EP-4493556-A1 NLRP3 MODULATORS Zomagen Biosciences Ltd (US) 2025-01-22 — — EP disclosed
US-20240390383-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES Zevra Denmark A/S (DK) 2024-11-28 — — US disclosed
EP-4466248-A1 LIPIDIC COMPOUNDS, AND USES THEREOF Sanofi (FR) 2024-11-27 — — EP disclosed
CN-118829624-A Lipid compound and use thereof 赛诺菲 2024-10-22 — — CN disclosed
EP-4408838-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES Zevra Denmark A/S (DK) 2024-08-07 — — EP disclosed
WO-2024129763-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
CN-118076599-A Dioxazines and their use in the treatment of GBA related diseases 泽拉丹麦有限公司 2024-05-24 — — CN disclosed
WO-2024067714-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY 泰励生物科技（上海）有限公司 2024-04-04 — — WO disclosed
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — US disclosed
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
EP-2009011-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-12-31 — — EP disclosed
EP-2009011-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-12-31 — — EP disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 — — WO disclosed
WO-2008045267-A2 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-04-17 — — WO disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TNNC1, CPT1B, TNNI3 HPGD 595/4885USP2 2796/4885SMN1; SMN2 438/4885
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 HPGD 3890/4885USP2 2766/4885SMN1; SMN2 3680/4885
US-20250114305-A1 LIPIDIC COMPOUNDS, AND USES THEREOF NR1H2, NR1H3, LPAR3 HPGD 2412/4885USP2 4227/4885SMN1; SMN2 3952/4885
US-20240390383-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES GBA1, GBA2, GBA3 HPGD 2007/4885USP2 2118/4885SMN1; SMN2 298/4885
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A HPGD 1055/4885USP2 2344/4885SMN1; SMN2 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.